Pfizer’s phase-III Jade trial shows positive results for moderate-to-severe atopic dermatitisa, Health News, ET HealthWorld
Pfizer recently announced that Jade Dare (B7451050), a 26-week, randomised, double-blind, double-dummy, active-controlled, multi-center phase-III study, met its co-primary and key secondary efficacy endpoints. The study showed that abrocitinib was…
